FDA Advisory Committee Will Review ESAs In The Renal Setting Oct. 18
This article was originally published in The Pink Sheet Daily
Executive Summary
Meeting also could be next step in the process of determining whether safety issues are enough to drive changes to erythropoiesis-stimulating agent reimbursement at CMS.